JD HEALTH

JD Health edged up today, rallying to a session high of 39.96 HKD at 10:42 Beijing time on strong Q4 earnings and ongoing management buybacks, but paring gains to close at 39.40 HKD in the afternoon as Hong Kong's cross-sector regulatory signals pressured sentiment, posting a +0.3% gain overall. Q4 revenues of 21.2 billion HKD rose 33.75% year-on-year with operating profit surging to 930 million HKD (up 1,265%), net profit climbing 36.72% to 1.55 billion HKD and EPS up 35.72% to 0.4837 HKD; Goldman Sachs maintained buy rating citing continued market share gains; the company is actively executing share repurchases. However, at 39.40 HKD the stock trades 45.05% below its 52-week high of 71.70 reached January 14 and has slid 30.08% year-to-date, reflecting persistent market concerns over tightening e-pharmacy regulations.

JD Health declined 1.8% to HK$39.28 today, primarily driven by ongoing regulatory scrutiny surrounding China's stricter drug e-commerce regulations. The stock opened higher at HK$40.50 but quickly weakened to HK$39.64 by late morning, then continued sliding to an intraday low of HK$39.14 in the afternoon. Despite regulatory headwinds, the company's fundamentals remain robust: Q4 operating revenue reached HK$21.21 billion, up 33.75% year-over-year, with net profit at HK$1.545 billion (up 36.72% YoY) and earnings per share of HK$0.4837 (up 35.72% YoY). Goldman Sachs maintains a Buy rating, citing continued market share expansion. The shareholder meeting approved all resolutions including ongoing share buybacks. Valuation-wise, the stock has declined 45.22% from its 52-week high of HK$71.7, trading at a relatively depressed level but still above its 60-day moving average of HK$38.73, with a market cap of approximately HK$125.3 billion.

JD Health edged up 0.48% to close at HK$37.96 today, as morning selling pressure was offset by afternoon recovery, prolonging consolidation patterns seen in recent weeks. Fundamental momentum contrasts with valuation headwinds—recent two quarters delivered revenue growth of 33.75% and 26.19%, net profit growth of 36.72% and 28.99%, and EPS growth of 35.72% and 28.05% year-over-year, yet the stock has fallen 32.64% year-to-date and sits 47% below its 52-week high of HK$71.70 set in January. Goldman Sachs maintained a buy rating recently, citing continued market share expansion, but pharmaceutical e-commerce regulatory tightening remains a headwind alongside recent governance shifts including equity restructuring, leaving investor concerns about business sustainability partially unresolved. Current valuations of PE 17.51 and PB 1.82 reflect material multiple compression from peak levels, though whether these prices adequately reflect regulatory and governance uncertainties requires further observation.

JD Health rose 2.1% to HK$37.78 today, supported by robust earnings and institutional endorsement. Q4 2025 results showed operating revenue of HK$21.1 billion, up 33.75% year-over-year, and net profit of HK$1.545 billion, up 36.72%, with operating profit surging 1265.69% year-on-year, reflecting significantly improved profitability. Goldman Sachs maintained its Buy rating, citing continued market share expansion. The stock's price action was constructive: the morning session opened at HK$37.04 and climbed to HK$37.90 by 11:27, with the afternoon session holding steady and closing at HK$37.78, suggesting market confidence in the internet-plus healthcare ecosystem. However, the stock remains down 32.95% year-to-date and 47.31% below the 52-week high of HK$71.70; at a PE of 17.42, valuations have normalized lower though lingering regulatory concerns from earlier periods may continue to temper investor sentiment.

JD Health declined 1.3% to close at HK$37.00 today, though the stock showed resilience during the session—morning weakness saw the stock test HK$36.64, but afternoon strength brought recovery to HK$37.00 at close. From a valuation perspective, the stock has fallen 34.34% year-to-date from an opening of HK$56.35 and remains 48.4% below its 52-week high of HK$71.7, though it has rebounded 16.21% from its June 25 low of HK$31.84. Q4 2025 financial results showed solid growth: revenue of HK$21.2 billion rose 33.75% year-over-year, net profit of HK$1.54 billion jumped 36.72%, and EPS climbed 35.72%, with the stock currently trading at a P/E of 17x. However, near-term sentiment remains pressured by stricter Chinese pharmaceutical e-commerce regulations; Goldman Sachs maintains a buy rating while UBS has cut its price target. The company's ongoing share repurchase program provides some price support.